Federal Register / Vol. 80, No. 64 / Friday, April 3, 2015 / Notices 18235 

trading in a range from 0 to 1⁄4 percent. 

The Committee directs the Desk to 

undertake open market operations as 

necessary to maintain such conditions. 

The Committee directs the Desk to 

maintain its policy of rolling over 

maturing Treasury securities into new 

issues and its policy of reinvesting 

principal payments on all agency debt 

and agency mortgage-backed securities 

in agency mortgage-backed securities. 

The Committee also directs the Desk to 

engage in dollar roll and coupon swap 

transactions as necessary to facilitate 

settlement of the Federal Reserve’s 

agency mortgage-backed securities 

transactions. The System Open Market 

Account manager and the secretary will 

keep the Committee informed of 

ongoing developments regarding the 

System’s balance sheet that could affect 

the attainment over time of the 

Committee’s objectives of maximum 

employment and price stability. 

By order of the Federal Open Market 

Committee, March 24, 2015. 

Thomas Laubach, 

Secretary, Federal Open Market Committee. 

[FR Doc. 2015–07708 Filed 4–2–15; 8:45 am] 

BILLING CODE 6210–01–P 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies 

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 

owned by the bank holding company, 

including the companies listed below. 

The applications listed below, as well 

as other related filings required by the 

Board, are available for immediate 

inspection at the Federal Reserve Bank 

indicated. The applications will also be 

available for inspection at the offices of 

the Board of Governors. Interested 

persons may express their views in 

writing on the standards enumerated in 

the BHC Act (12 U.S.C. 1842(c)). If the 

proposal also involves the acquisition of 

a nonbanking company, the review also 

includes whether the acquisition of the 

nonbanking company complies with the 

standards in section 4 of the BHC Act 

(12 U.S.C. 1843). Unless otherwise 

noted, nonbanking activities will be 

conducted throughout the United States. 

Unless otherwise noted, comments 

regarding each of these applications 

must be received at the Reserve Bank 

indicated or the offices of the Board of 

Governors not later than April 30, 2015. 

A. Federal Reserve Bank of Chicago 

(Colette A. Fried, Assistant Vice 

President) 230 South LaSalle Street, 

Chicago, Illinois 60690–1414: 

1. Foresight Financial Group, Inc., 

Rockford, Illinois; to acquire 100 

percent of the voting shares of State 

Bank of Herscher, Herscher, Illinois. 

Board of Governors of the Federal Reserve 

System, March 31, 2015. 

Michael J. Lewandowski, 

Associate Secretary of the Board. 

[FR Doc. 2015–07663 Filed 4–2–15; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2011–F–0172] 

Agency Information Collection 

Activities; Announcement of Office of 

Management and Budget Approval; 

Food Labeling; Nutrition Labeling of 

Standard Menu Items in Restaurants 

and Similar Retail Food 

Establishments 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a collection of information entitled, 

‘‘Food Labeling; Nutrition Labeling of 

Standard Menu Items in Restaurants 

and Similar Retail Food 

Establishments,’’ has been approved by 

the Office of Management and Budget 

(OMB) under the Paperwork Reduction 

Act of 1995. 

FOR FURTHER INFORMATION CONTACT: FDA 

PRA Staff, Office of Operations, Food 

and Drug Administration, 8455 

Colesville Rd., COLE–14526, Silver 

Spring, MD 20993–0002, PRAStaff@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: On 

February 5, 2015, the Agency submitted 

a proposed collection of information 

entitled ‘‘Food Labeling; Nutrition 

Labeling of Standard Menu Items in 

Restaurants and Similar Retail Food 

Establishments’’ to OMB for review and 

clearance under 44 U.S.C. 3507. An 

Agency may not conduct or sponsor, 

and a person is not required to respond 

to, a collection of information unless it 

displays a currently valid OMB control 

number. OMB has now approved the 

information collection and has assigned 

OMB control number 0910–0783. The 

approval expires on March 31, 2018. A 

copy of the supporting statement for this 

information collection is available on 

the Internet at http://www.reginfo.gov/

public/do/PRAMain. 

Dated: March 30, 2015. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2015–07655 Filed 4–2–15; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2015–N–0001] 

Request for Nominations for 

Individuals and Consumer 

Organizations for Advisory 

Committees 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is requesting that 

any consumer organizations interested 

in participating in the selection of 

voting and/or nonvoting consumer 

representatives to serve on its advisory 

committees or panels notify FDA in 

writing. FDA is also requesting 

nominations for voting and/or 

nonvoting consumer representatives to 

serve on advisory committees and/or 

panels for which vacancies currently 

exist or are expected to occur in the near 

future. Nominees recommended to serve 

as a voting or nonvoting consumer 

representative may be self-nominated or 

may be nominated by a consumer 

organization. Nominations will be 

accepted for current vacancies and for 

those that will or may occur through 

September 30, 2015. 

DATES: Any consumer organization 

interested in participating in the 

selection of an appropriate voting or 

nonvoting member to represent 

consumer interests on an FDA advisory 

committee or panel may send a letter or 

email stating that interest to the FDA 

(see ADDRESSES) by May 4, 2015, for 

vacancies listed in this notice. 

Concurrently, nomination materials for 

prospective candidates should be sent to 

FDA (see ADDRESSES) by May 4, 2015. 

ADDRESSES: All statements of interest 

from consumer organizations interested 

in participating in the selection process 

and consumer representative 

nominations should submit your 

information electronically to 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
18236 Federal Register / Vol. 80, No. 64 / Friday, April 3, 2015 / Notices 

kimberly.hamilton@fda.hhs.gov or by 

mail to Advisory Committee Oversight 

and Management Staff, 10903 New 

Hampshire Ave., Bldg. 32, Rm. 5103, 

Silver Spring, MD 20993–0002, or FAX: 

301–847–8640. 

Consumer Representative 

nominations should be submitted 

electronically by logging into the FDA 

advisory Committee Membership 

Nomination Portal: https://

www.accessdata.fda.gov/scripts/

FACTRSPortal/FACTRS/index.cfm or by 

mail to Advisory Committee Oversight 

and Management Staff, 10903 New 

Hampshire Ave., Bldg. 32, Rm. 5103, 

Silver Spring, MD 20993–0002, or FAX: 

301–847–8640. Additional information 

about becoming a member on an FDA 

advisory committee can also be obtained 

by visiting FDA’s Web site at http://

www.fda.gov/AdvisoryCommittees/

default.htm. 

FOR FURTHER INFORMATION CONTACT: 

Kimberly Hamilton, Advisory 

Committee Oversight and Management 

Staff, Food and Drug Administration, 

10903 New Hampshire Ave., Bldg. 32, 

Rm. 5117, Silver Spring, MD 20993– 

0002;. 301–796–8224, email: 

kimberly.hamilton@fda.hhs.gov. 

For questions relating to specific 

advisory committees or panels, contact 

the following persons listed in table 1 of 

this document: 

TABLE 1—ADVISORY COMMITTEE CONTACTS

Contact person Committee/Panel 

Janie Kim, Center for Biologics Evaluation and Research, Food and Drug Administration, 

10903 New Hampshire Ave., Bldg. 71, Rm. 6129, Silver Spring, MD 20993; 301–796–9016, 

email: Janie.Kim@fda.hhs.gov.

Allergenic Products Advisory Committee. 

Stephanie Begansky, Center for Drug Evaluation and Research, Division of Advisory Committee and Consultant Management, Office of Executive Programs, 10903 New Hampshire 

Ave., Bldg. 31, Rm. 2426, Silver Spring, MD 20993–0002; 301–796–3693, FAX: 301–847– 

8533, email: Stephanie.Begansky@fda.hhs.gov.

Arthritis Advisory Committee. 

Jamie Waterhouse, Center for Devices and Radiological Health, Office of Device Evaluation, 

10903 New Hampshire Ave., Bldg. 66, Rm. 1544, Silver Spring, MD 20993–0002; 301–796– 

3063, FAX: 301–847–8122, email: Jamie.Waterhouse@fda.hhs.gov.

Circulatory System Devices Panel, Molecular 

and Clinical Genetics Panel. 

Yvette Waples, Center for Drug Evaluation & Research, Division of Advisory Committee and 

Consultant Management, Office of Executive Programs, 10993 New Hampshire Ave., Bldg. 

31, Rm. 2510, Silver Spring, MD 20993–0002; 301–796–9034 FAX: 301–847–8533 email: 

Yvette.Waples@fda.hhs.gov.

Dermatologic and Ophthalmic Drugs Advisory 

Committee. 

Patricio Garcia, Center for Devices and Radiological Health, Office of Device Evaluation, 10903 

New Hampshire Ave., Bldg. 66, Rm. RMG 465 HFZ–410, Silver Spring, MD 20903–0002, 

301–796–6875, FAX: 301–847–8120, email: Patricio.Garcia@fda.hhs.gov.

General and Plastic Surgery Devices Panel. 

Sara J. Anderson, Center for Devices and Radiological Health, Office of Device Evaluation, 

10903 New Hampshire Ave., Bldg. 66, Rm. 1544, Silver Spring, MD 20903–0002; 301–796– 

7047, FAX: 301–847–8122, email: Sara.Anderson@fda.hhs.gov.

Hematology & Pathology Devices Panel, 

Orthopaedic and Rehabilitation Devices 

Panel, and National Mammography and 

Quality Assurance Advisory Committee. 

Shanika Craig, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66 Rm. 

1613, Silver Spring, MD 20993–0002; 301–796–6639, FAX: 301–847–8120, email: 

Shanika.Craig@fda.hhs.gov.

Obstetrics and Gynecology Devices Panel. 

Lauren Tesh, Center for Drug Evaluation and Research, 10903 New Hampshire Ave., Bldg. 31, 

Rm. 2426, Silver Spring, MD 20993–0002; 301–796–2721, email: Lauren.Tesh@fda.hhs.gov.

Oncologic Drugs Advisory Committee. 

Donna Mendrick, National Center for Toxicological Research, Bldg. 32, Rm. 2208, 10903 New 

Hampshire Ave., Silver Spring, MD 20993–0002, 301–796–8892, FAX: 301–847–8600, 

email: Donna.Mendrick@fda.hhs.gov.

Science Advisory Board to National Center for 

Toxicological Research (NCTR). 

Sujata Vijh, Center for Biologics Evaluation and Research, Division of Scientific Advisors and 

Consultants, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002; 240–402–7107, 

FAX: 301–595–1307, email: Sujata.Vijh@fda.hhs.gov.

Vaccines and Related Biological Products Advisory Committee. 

SUPPLEMENTARY INFORMATION: FDA is 

requesting nominations for voting and/ 

or nonvoting consumer representatives 

for the vacancies listed in Table 2: 

TABLE 2—COMMITTEE DESCRIPTIONS, TYPE OF CONSUMER VACANCY, AND APPROXIMATE DATE NEEDED

Committee/Panel/Areas of expertise needed Current and upcoming vacancies 

Approximate date 

needed 

Allergenic Products Advisory Committee: Knowledgeable in the fields of allergy, immunology, pediatrics, internal medicine, biochemistry, and related specialties.One Voting .............. June 30, 2015. 

Arthritis Drugs Advisory Committee: Knowledgeable in the fields of arthritis, rheumatology, orthopedics, epidemiology or statistics, analgesics, and related specialties.One Voting .............. September 30, 2015. 

Circulatory System Devices Panel of the Medical Devices Advisory Committee: Knowledgeable in 

the safety and effectiveness of marked and investigational devices for use in the circulatory and 

vascular systems.

One Non-Voting ....... Immediately. 

Dermatologic & Ophthalmic Drugs Advisory Committee: Knowledgeable in the fields of dermatology, ophthalmology, internal medicine, pathology, immunology, epidemiology or statistics, 

and other related professions.

One Voting .............. August 31, 2015. 

General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee: Knowledgeable in the fields of general, plastic, reconstructive, pediatric, thoracic, abdominal, pelvic 

and endoscopic surgery; biomaterials, lasers, wound healing, and quality of life issues.

One Non-Voting ....... Immediately. 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 64 / Friday, April 3, 2015 / Notices 18237 

TABLE 2—COMMITTEE DESCRIPTIONS, TYPE OF CONSUMER VACANCY, AND APPROXIMATE DATE NEEDED—Continued 

Committee/Panel/Areas of expertise needed Current and upcoming vacancies 

Approximate date 

needed 

Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee: Knowledgeable in the fields of hematology, hematopathology, coagulation and homeostasis, 

hematological oncology, gynecological oncology.

One Non-Voting ....... Immediately. 

Molecular & Clinical Genetics Panel of the Medical Devices Advisory Committee: Experts in 

human genetics and in the clinical management of patients with genetic disorders, e.g., pediatricians, obstetricians, neonatologists. The Agency is also interested in considering candidates 

with training in inborn errors of metabolism, biochemical and/or molecular genetics, population 

genetics, epidemiology and related statistical training. Additionally, individuals with experience 

in genetic counseling, medical ethics as well as ancillary fields of study will be considered.

One Non-Voting ....... May 31, 2015. 

Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee: Knowledgeable in the fields of perinatology, embryology, reproductive endocrinology, pediatric gynecology, gynecological oncology, operative hysteroscopy, pelviscopy, electrosurgery, laser surgery, assisted reproductive technologies, contraception, postoperative adhesions, and cervical 

cancer and colposcopy; obstetrics/gynecology devices; gynecology in the older patient; midwifery; labor and delivery nursing.

One Non-Voting ....... Immediately. 

Oncologic Drugs Advisory Committee: Knowledgeable in the fields of general oncology, pediatric 

oncology, hematologic oncology, immunologic oncology, biostatistics, and other related professions.

One Voting .............. Immediately. 

National Mammography Quality Assurance Advisory Committee: Knowledgeable in clinical practice, research specialization, or professional work that has a significant focus on mammography.Two Voting .............. Immediately. 

Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee: 

Knowledgeable in data concerning the safety and effectiveness of marketed and investigational 

orthopaedic and rehabilitation devices.

Two Non-Voting ....... Immediately. 

Science Advisory Board to the NCTR: Knowledgeable in the fields related to toxicological research.One Voting .............. June 30, 2015. 

Vaccines and Related Biological Products Advisory Committee Knowledgeable in the fields of immunology, molecular biology, rDNA, virology, bacteriology, epidemiology or biostatistics, allergy, 

preventive medicine, infectious diseases, pediatrics, microbiology, and biochemistry.

One Voting .............. Immediately. 

I. Functions 

A. Allergenic Products Advisory 

Committee: Reviews and evaluates 

available data concerning the safety, 

effectiveness, and adequacy of labeling 

of marketed and investigational 

allergenic biological products or 

materials that are administered to 

humans for the diagnosis, prevention, or 

treatment of allergies and allergic 

disease as well as the affirmation or 

revocation of biological product 

licenses, on the safety, effectiveness, 

and labeling of the products, on clinical 

and laboratory studies of such products, 

on amendments or revisions to 

regulations governing the manufacture, 

testing and licensing of allergenic 

biological products, and on the quality 

and relevance of FDA’s research 

programs. 

B. Arthritis Drugs Advisory 

Committee: Reviews and evaluates data 

concerning the safety and effectiveness 

of marketed and investigational human 

drug products for use in the treatment 

of arthritis, rheumatism, and related 

diseases. 

C. Certain Panels of the Medical 

Devices Advisory Committee: The 

committee reviews and evaluates data 

on the safety and effectiveness of 

marketed and investigational devices 

and makes recommendations for their 

regulation. The panels engage in a 

number of activities to fulfill the 

functions the Federal Food, Drug, and 

Cosmetic Act (the FD&C Act) envisions 

for device advisory panels. With the 

exception of the Medical Devices 

Dispute Resolution Panel, each panel, 

according to its specialty area, advises 

the Commissioner of Food and Drugs 

(the Commissioner) regarding 

recommended classification or 

reclassification of devices into one of 

three regulatory categories, advises on 

any possible risks to health associated 

with the use of devices, advises on 

formulation of product development 

protocols, reviews premarket approval 

applications for medical devices, 

reviews guidelines and guidance 

documents, recommends exemption of 

certain devices from the application of 

portions of the FD&C Act, advises on the 

necessity to ban a device, and responds 

to requests from the Agency to review 

and make recommendations on specific 

issues or problems concerning the safety 

and effectiveness of devices. With the 

exception of the Medical Devices 

Dispute Resolution Panel, each panel, 

according to its specialty area, may also 

make appropriate recommendations to 

the commissioner on issues relating to 

the design of clinical studies regarding 

the safety and effectiveness of marketed 

and investigational devices. 

D. Dermatologic and Ophthalmic 

Drugs Advisory Committee: Reviews 

and evaluates available data concerning 

the safety and effectiveness of marketed 

and investigational human drug 

products for use in the treatment of 

dermatologic and ophthalmic disorders. 

E. National Mammography and 

Quality Assurance Advisory Committee: 

The committee reviews and evaluates 

(1) Developing appropriate quality 

standards and regulations for 

mammography facilities; (2) developing 

appropriate standards and regulations 

for bodies accrediting mammography 

facilities under this program; (3) 

developing regulations with respect to 

sanctions; (4) developing procedures for 

monitoring compliance with standards; 

(5) establishing a mechanism to 

investigate consumer complaints; (6) 

reporting new developments concerning 

breast imaging which should be 

considered in the oversight of 

mammography facilities; (7) 

determining whether there exists a 

shortage of mammography facilities in 

rural and health professional shortage 

areas and determining the effects of 

personnel on access to the services of 

such facilities in such areas; (8) 

determining whether there will exist a 

sufficient number of medical physicists 

after October 1, 1999; and (9) 

determining the costs and benefits of 

compliance with these requirements. 

F. Oncologic Drugs Advisory 

Committee: Reviews and evaluates data 

concerning the safety and effectiveness 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
18238 Federal Register / Vol. 80, No. 64 / Friday, April 3, 2015 / Notices 

of marketed and investigational human 

drug products for use in the treatment 

of cancer. 

G. Science Advisory Board to the 

National Center for Toxicological 

Research: Reviews and advises the 

Agency on the establishment, 

implementation and evaluation of the 

research programs and regulatory 

responsibilities as it relates to NCTR. 

The Board will also provide an extraAgency review in ensuring that the 

research programs at NCTR are 

scientifically sound and pertinent. 

H. Vaccines and Related Biological 

Products Advisory Committee: Reviews 

and evaluates data concerning the 

safety, effectiveness, and appropriate 

use of vaccines and related biological 

products which are intended for use in 

the prevention, treatment, or diagnosis 

of human diseases, as well as considers 

the quality and relevance of FDA’s 

research program which provides 

scientific support for the regulation of 

these products. 

II. Criteria for Members 

Persons nominated for membership as 

consumer representatives on 

committees or panels should meet the 

following criteria: (1) Demonstrate ties 

to consumer and community-based 

organizations, (2) be able to analyze 

technical data, (3) understand research 

design, (4) discuss benefits and risks, 

and (5) evaluate the safety and efficacy 

of products under review. The 

consumer representative should be able 

to represent the consumer perspective 

on issues and actions before the 

advisory committee; serve as a liaison 

between the committee and interested 

consumers, associations, coalitions, and 

consumer organizations; and facilitate 

dialogue with the advisory committees 

on scientific issues that affect 

consumers. 

III. Selection Procedures 

Selection of members representing 

consumer interests is conducted 

through procedures that include the use 

of organizations representing the public 

interest and public advocacy groups. 

These organizations recommend 

nominees for the Agency’s selection. 

Representatives from the consumer 

health branches of Federal, State, and 

local governments also may participate 

in the selection process. Any consumer 

organization interested in participating 

in the selection of an appropriate voting 

or nonvoting member to represent 

consumer interests should send a letter 

stating that interest to FDA (see 

ADDRESSES) within 30 days of 

publication of this document. 

Within the subsequent 30 days, FDA 

will compile a list of consumer 

organizations that will participate in the 

selection process and will forward to 

each such organization a ballot listing at 

least two qualified nominees selected by 

the Agency based on the nominations 

received, together with each nominee’s 

current curriculum vitae or resume. 

Ballots are to be filled out and returned 

to FDA within 30 days. The nominee 

receiving the highest number of votes 

ordinarily will be selected to serve as 

the member representing consumer 

interests for that particular advisory 

committee or panel. 

IV. Nomination Procedures 

Any interested person or organization 

may nominate one or more qualified 

persons to represent consumer interests 

on the Agency’s advisory committees or 

panels. Self-nominations are also 

accepted. Nominations should include a 

cover letter and a current curriculum 

vitae or resume for each nominee, 

including a current business and/or 

home address, telephone number, and 

email address if available, and a list of 

consumer or community-based 

organizations for which the candidate 

can demonstrate active participation. 

FDA seeks to include the views of 

women and men, members of all racial 

and ethnic groups, and individuals with 

and without disabilities on its advisory 

committees and therefore, encourages 

nominations of appropriately qualified 

candidates from these groups. 

Nominations should also specify the 

advisory committee(s) or panel(s) for 

which the nominee is recommended. In 

addition, nominations should include 

confirmation that the nominee is aware 

of the nomination, unless selfnominated. FDA will ask potential 

candidates to provide detailed 

information concerning such matters as 

financial holdings, employment, and 

research grants and/or contracts to 

permit evaluation of possible sources of 

conflicts of interest. Members will be 

invited to serve for terms up to 4 years. 

FDA will review all nominations 

received within the specified 

timeframes and prepare a ballot 

containing the names of qualified 

nominees. Names not selected will 

remain on a list of eligible nominees 

and be reviewed periodically by FDA to 

determine continued interest. Upon 

selecting qualified nominees for the 

ballot, FDA will provide those 

consumer organizations that are 

participating in the selection process 

with the opportunity to vote on the 

listed nominees. Only organizations 

vote in the selection process. Persons 

who nominate themselves to serve as 

voting or nonvoting consumer 

representatives will not participate in 

the selection process. 

Dated: March 30, 2015. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2015–07605 Filed 4–2–15; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–15–0929] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) has submitted the 

following information collection request 

to the Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995. The notice for 

the proposed information collection is 

published to obtain comments from the 

public and affected agencies. 

Written comments and suggestions 

from the public and affected agencies 

concerning the proposed collection of 

information are encouraged. Your 

comments should address any of the 

following: (a) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the functions of the agency, including 

whether the information will have 

practical utility; (b) Evaluate the 

accuracy of the agencies estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; (d) Minimize the burden of 

the collection of information on those 

who are to respond, including through 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and (e) Assess information 

collection costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570 or 

send an email to omb@cdc.gov. Written 

comments and/or suggestions regarding 

the items contained in this notice 

should be directed to the Attention: 

CDC Desk Officer, Office of Management 

and Budget, Washington, DC 20503 or 

by fax to (202) 395–5806. Written 


asabaliauskas on DSK5VPTVN1PROD with NOTICES